menu
    • menu
    [{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"OPK88001","moa":"SCN1A","graph1":"Neurology","graph2":"Preclinical","graph3":"CAMP4 Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ CAMP4 Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"CAMP4 Therapeutics \/ CAMP4 Therapeutics"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Coastlands Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Private Placement","leadProduct":"CMP-SYNGAP","moa":"SYNGAP1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CAMP4 Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Coastlands Capital","highestDevelopmentStatusID":"4","companyTruncated":"CAMP4 Therapeutics \/ Coastlands Capital"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"CAMP4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"CAMP4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"CAMP4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"CAMP4 Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"CAMP4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"CAMP4 Therapeutics \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Fulcrum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"CAMP4 Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Fulcrum Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"CAMP4 Therapeutics \/ Fulcrum Therapeutics"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Therapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Janus Henderson Investors | Coastlands Capital | EcoR1 Capital | Trails Edge Capital Partners | Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Public Offering","leadProduct":"Vidutolimod","moa":"CPS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"CAMP4 Therapeutics \/ Janus Henderson Investors | Coastlands Capital | EcoR1 Capital | Trails Edge Capital Partners | Vivo Capital","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Janus Henderson Investors | Coastlands Capital | EcoR1 Capital | Trails Edge Capital Partners | Vivo Capital"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"CAMP4 Therapeutics \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals by CAMP4 Therapeutics

    Menu

    CAMP4 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vidutolimod

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Janus Henderson Investors | Coastlands Capital | EcoR1 Capital | Trails Edge Capital Partners | Vivo Capital

                            Deal Size : $30.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Camp4 Sets Price for $30M Stock Offering

                            Details : The proceeds from the offering will be used to fund the clinical development of CMP-001, an oligonucleotide targeting CPS1 for Urea Cycle Disorder.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 18, 2025

                            Lead Product(s) : Vidutolimod

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Janus Henderson Investors | Coastlands Capital | EcoR1 Capital | Trails Edge Capital Partners | Vivo Capital

                            Deal Size : $30.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Camp4, GSK Collaborate to Advance RNA Therapeutic Discoveries

                            Details : The collaboration aims to advance the development of an undisclosed oligonucleotide for neurodegenerative diseases.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : $17.5 million

                            December 18, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMP-SYNGAP

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Coastlands Capital

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million

                            Details : CAMP4 intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its SYNGAP1 program, CMP-SYNGAP.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            September 10, 2025

                            Lead Product(s) : CMP-SYNGAP

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Coastlands Capital

                            Deal Size : $100.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            CAMP4 Announces Pricing of Initial Public Offering

                            Details : The proceeds will advance the development of CMP-CPS-001, designed to upregulate CPS1 gene expression by binding to a CPS1-specific regulatory RNA sequence, for the treatment of Urea cycle disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery Platform

                            Sponsor : BioMarin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CAMP4 Partners on Research to Develop RNA-Targeting Medicines for Rare Diseases

                            Details : The collaboration combines BioMarin’s expertise in drug development with CAMP4’s platform-based target discovery capabilities to advance novel regRNA-targeting medicines for rare genetic conditions.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery Platform

                            Sponsor : BioMarin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAMP4 Secures Orphan Drug Status For CMP-CPS-001 in Urea Cycle Disorders

                            Details : CMP-CPS-001 is an ASO designed to amplify CPS1 mRNA by harnessing fundamental cellular gene expression control mechanisms. It is being evaluated for the treatment of urea cycle disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 17, 2024

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAMP4 Wins Rare Pediatric Disease Designation for Urea Cycle Disorder Treatment

                            Details : CMP-CPS-001 is an ASO designed to amplify CPS1 mRNA by harnessing fundamental cellular gene expression control mechanisms. It is being evaluated for the treatment of urea cycle disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2024

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAMP4 Doses First Participant in Phase 1 Study of CMP-CPS-001 for Urea Cycle Disorders

                            Details : CMP-CPS-001 is an antisense oligonucleotide (ASO) designed to amplify CPS1 mRNA by harnessing fundamental cellular gene expression control mechanisms. It is being evaluated for urea cycle disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 21, 2024

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of CMP-CPS-001 in Healthy Volunteers

                            Details : CMP-CPS-001 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 08, 2024

                            Lead Product(s) : CMP-CPS-001

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            CAMP4 Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Fulcrum Therapeutics

                            Deal Size : $70.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

                            Details : Fulcrum gains worldwide license to intellectual property arising from CAMP4’s DBA program, including the rights for discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of D...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 10, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Fulcrum Therapeutics

                            Deal Size : $70.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.